Barham, United Kingdom

Michael G Collis

This inventor holds 3 USPTO granted patents. Top assignee: Imperial Chemical Industries Limited. Active years: 1993-1994.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 3

Forward Citations = 16(Granted Patents)


Location History:

  • Macclesfield, GB (1993)
  • Barham, GB (1993 - 1994)

Company Filing History:


Years Active: 1993-1994

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Michael G Collis

Introduction

Michael G Collis is a notable inventor based in Barham, GB. He has made significant contributions to the field of chemistry, particularly in the development of novel compounds. With a total of 3 patents to his name, Collis has demonstrated a commitment to innovation and scientific advancement.

Latest Patents

Among his latest patents, Collis has developed azole derivatives, which are compounds characterized by a specific formula. These compounds include variations where R.sup.1 can be hydrogen, (1-6C)alkyl, or (1-4C)alkanoyl. Additionally, he has worked on [1,2,4]-Triazolo[1,5-a] and pyrazolo[2,3-a][1,3,5]triazine derivatives. This invention focuses on novel, pharmaceutically useful compounds of formula I, where Q is a 5-membered heteroaryl that may bear one or two substituents independently selected from (1-4C)alkyl and halogeno.

Career Highlights

Collis is associated with Imperial Chemical Industries Limited, a company known for its contributions to the chemical industry. His work has been instrumental in advancing pharmaceutical chemistry, showcasing his expertise and innovative spirit.

Collaborations

Throughout his career, Collis has collaborated with esteemed colleagues such as Geraint Jones and Peter W Caulkett. These partnerships have likely enriched his research and contributed to the success of his inventions.

Conclusion

Michael G Collis stands out as a prominent inventor in the field of chemistry, with a focus on developing innovative compounds. His contributions through patents and collaborations reflect his dedication to advancing scientific knowledge and pharmaceutical applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…